Pledge Therapeutics
0726.743.301 · rovalta.com · 24/09/2026
ACTIVE
Pledge Therapeutics
Financial year 2024 · closed on 31/12/2024
Net result
-688,8 k €
-23.3% YoY
Gross margin
-97,5 k €
+32.4% YoY
Equity
-2,4 M €
-40.3% YoY
Workforce
5,9 ETP
+43.9% YoY
Overview
What does Pledge Therapeutics do?
Pledge Therapeutics is a Private limited company incorporated in 2019. Its main activity is: Manufacture of basic pharmaceutical products. Its registered office is in Leuven. It employs on average 5,9 ETP workers (FTE).
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0726.743.301
Incorporation
14/05/2019
Legal form
Private limited company
Registered office
Gaston Geenslaan 1
3001 Leuven · FlandreSee on map
3001 Leuven · FlandreSee on map
Contributed capital
500,00 €
Latest accounts
31/12/2024
Average workforce
5,9 ETP
Activities (NACE)
Signals
Healthy social debts
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 5 financial years
| 2024 | 2023 | 2022 | 2021 | 2020 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | -97,5 k € | +32.4% | -144,2 k € | -62.1% | -88,9 k € | +11.1% | -100 k € | +15.9% | -118,9 k € |
| EBITDA | -644,6 k € | -24.5% | -517,7 k € | -39.6% | -370,9 k € | -20.0% | -309,1 k € | +23.7% | -405,2 k € |
| Operating result | -689,2 k € | -23.3% | -559,1 k € | -37.5% | -406,6 k € | -24.9% | -325,5 k € | +21.1% | -412,5 k € |
| Net result | -688,8 k € | -23.3% | -558,7 k € | -36.8% | -408,5 k € | -25.3% | -326,1 k € | +21.4% | -414,8 k € |
| Balance sheet | |||||||||
| Equity | -2,4 M € | -40.3% | -1,7 M € | -48.6% | -1,1 M € | -55.2% | -740,3 k € | -78.7% | -414,3 k € |
| Total assets | 292,4 k € | -19.1% | 361,3 k € | +5.0% | 344,2 k € | +9.7% | 313,8 k € | +277% | 83,3 k € |
| Cash | 35,2 k € | -57.3% | 82,5 k € | +68.8% | 48,9 k € | +184% | 17,2 k € | +98.4% | 8,7 k € |
| Debts | 2,7 M € | +29.8% | 2,1 M € | +38.6% | 1,5 M € | +41.7% | 1,1 M € | +113% | 493,8 k € |
| Other | |||||||||
| Workforce | 5,9 ETP | +43.9% | 4,1 ETP | +17.1% | 3,5 ETP | +16.7% | 3,0 ETP | 0.0% | 3,0 ETP |
Governance
Board of directors
Seen on filing of 31/12/2024 · 1 active · 2 ended
Active mandates
ALI MUNAWAR
ActiveEnded mandates
OrthogonX Therapeutics LLC BO
EndedPledge Therapeutics LLC BO
EndedAt this address
Other companies at this address
| Company | CBE no. |
|---|---|
ALIGOS BELGIUM● Active | 0702.969.886 |
Bio-Incubator Leuven● Active | 0876.605.232 |
Community Building Arenberg● Active | 1014.096.594 |
Creative Biolabs Belgium● Active | 1028.942.544 |
DName-iT● Active | 0506.754.823 |
Fisherman● Active | 0804.287.079 |
Fishway● Active | 0787.869.632 |
Formac Pharmaceuticals● Active | 0892.914.395 |
IDA INTERNATIONAL● Active | 1002.119.470 |
Lever Bio Belgium● Active | 1039.455.958 |
Maatschap reMYND● Active | 1019.655.090 |
miDiagnostics● Active | 0641.984.602 |
Oxurion● Active | 0881.620.924 |
PALEO● Active | 0756.986.614 |
PARKEERGEBOUW● Active | 1009.039.728 |
Qmineral● Active | 0837.633.897 |
Raya Therapeutic● Active | 1003.128.171 |
ReGenesys● Active | 0877.070.337 |
ReGenesys EU● Active | 0544.577.301 |
reMYND● Active | 0476.910.101 |
Financials
Annual accounts
Full financial information
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 14/05/2019 |
| Closing of the financial year | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 20 months |
| Filing date | 29/09/2025 | 30/09/2024 | 31/08/2023 | 16/09/2022 | 31/08/2021 |
| General meeting | 13/06/2025 | 14/06/2024 | 09/06/2023 | 10/06/2022 | 30/06/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
5 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2024 | 13/06/2025 | 29/09/2025 | Dutch | |
| Abridged model | 31/12/2023 | 14/06/2024 | 30/09/2024 | Dutch | |
| Abridged model | 31/12/2022 | 09/06/2023 | 31/08/2023 | Dutch | |
| Abridged model | 31/12/2021 | 10/06/2022 | 16/09/2022 | Dutch | |
| Abridged model | 31/12/2020 | 30/06/2021 | 31/08/2021 | Dutch |
Valuation
Estimate
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 31/12/2024 · 1 active · 2 ended
Active mandates
ALI MUNAWAR
ActiveEnded mandates
OrthogonX Therapeutics LLC BO
EndedPledge Therapeutics LLC BO
EndedShareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2024Annual accounts 2024-688,8 k €↓
- 2023Annual accounts 2023-558,7 k €↓
- 2022Annual accounts 2022-408,5 k €↓
- 2021Annual accounts 2021-326,1 k €↑
- 2020Annual accounts 2020-414,8 k €
- 14/05/2019IncorporationPrivate limited company